| 1929-04 |
April 1929: Established the partnership company "Nutrition and Childcare Association" at Shiba Park, Shiba-ku, Tokyo, and launched "Wakimoto". |
| 1929-04 |
Established a joint‑stock company "Nutrition and Childcare Association" at Daimon, Shiba Park, Shiba‑ku, Tokyo City, and launched "Wakamoto". |
| 1933-01 |
January 1933: Established "Nutrition and Childcare Association Co., Ltd." in Shiba Park, Shiba-ku, Tokyo, and began manufacturing and selling the digestive, intestinal, and nutritional agent "Wakimoto". |
| 1933-01 |
Established "Corporation Nutrition and Childcare Association" in Shiba Park, Shiba‑ku, Tokyo City, and began manufacturing and selling the digestive, intestinal health, and nutrition agent "Wakamoto". |
| 1935-12 |
December 1935: Renamed the company to "Wakimoto Honpo Nutrition and Childcare Association Co., Ltd.". |
| 1935-12 |
Renamed the company name to "Corporation Wakamoto Honpo Nutrition and Childcare Association". |
| 1943-07 |
July 1943: Renamed the company to its current name "Wakimoto Pharmaceutical Co., Ltd.". |
| 1943-07 |
Renamed the company name to the current "Wakamoto Pharmaceutical Co., Ltd.". |
| 1949-05 |
May 1949: Listed on the Tokyo Stock Exchange. |
| 1949-05 |
Listed on the Tokyo Stock Exchange |
| 1955 |
Since its founding, our company has developed products that contribute to the health maintenance of the public by utilizing lactic acid bacteria technology. In 1955, we incorporated lactic acid bacteria into "Wakamoto". |
| 1955 |
Added lactic acid bacteria to 'Wakamoto'. |
| 1962-01 |
January 1962: Released "Kouryoku Wakimoto", an enhanced product featuring digestive enzymes, active lactic acid bacteria, vitamins B1 and B2, and nicotinamide. |
| 1962-01 |
Released 'Strong Wakamoto' with enhanced digestive enzymes, active lactic acid bacteria, vitamins B1, B2, and nicotinamide |
| 1968-06 |
June 1968: Established the Sagami-Oi factory and research facilities in Oi-machi, Sagamihara, Kanagawa Prefecture. |
| 1968-06 |
Established the Sagami Oi factory and research facilities in Oi-machi, Sagamihara, Kanagawa Prefecture |
| 1970 |
In 1970, we began selling the antibiotic and chemotherapy‑resistant lactic acid bacteria formulation "Rebenin". |
| 1970 |
Started sales of antibiotic and chemotherapy-resistant lactic acid bacteria formulation 'Rebenin'. |
| 1983-08 |
August 1983: Launched the medicated toothpaste "Coral" (now Coral ε). |
| 1983-08 |
Released medicinal toothpaste 'Coral' (now Coral ε) |
| 1983-09 |
September 1983: Listed on the First Section of the Tokyo Stock Exchange. |
| 1983-09 |
Listed on the First Section of the Tokyo Stock Exchange |
| 1989-01 |
January 1989: Issued the first series of secured convertible bonds with a total face value of 4 billion yen. |
| 1989-01 |
Issued the first series of asset-backed convertible bonds with a total face value of 4 billion yen |
| 1989-05 |
May 1989: Released the water-soluble non-steroidal anti-inflammatory eye drop "Dicloid Eye Drops 0.1%". |
| 1989-05 |
Released aqueous non-steroidal anti-inflammatory eye drop 'Dicloid 0.1%' |
| 1995 |
In 1995, we sold "Wakamoto Intestinal Health Medicine", the first over‑the‑counter product to incorporate two strains of Bifidobacteria. |
| 1995 |
Sold 'Wakamoto Intestinal Health Medicine', the first over-the-counter drug to combine two Bifidobacterium strains. |
| 1995-12 |
December 1995: Released the lactic acid bacteria intestinal regulator "Wakimoto Intestinal Medicine". |
| 1995-12 |
Released lactic acid bacteria intestinal regulator 'Wakamojo Seichouyaku' |
| 1999-11 |
November 1999: Released "Rizmon TG Eye Drops", the world's first heat-responsive gel technology eye drop for glaucoma and ocular hypertension. |
| 1999-11 |
Released the world's first thermoresponsive gel technology eye drop, glaucoma and ocular hypertension treatment 'Rizmon TG Eye Drop' |
| 2000-11 |
November 2000: Released "Zepelin Eye Drops 0.1%" for allergic conjunctivitis. |
| 2000-11 |
Released allergy conjunctivitis treatment 'Zepelin 0.1% eye drop' |
| 2002-08 |
August 2002: Obtained ISO 14001 certification for the environmental management system at the Sagami-Oi factory. |
| 2002-08 |
Obtained ISO 14001 certification for the Sagami Oi factory environmental management system |
| 2005 |
In 2005, we sold "AvanBees", the first Japanese medicated toothpaste containing live lactic acid bacteria. |
| 2005 |
Sold 'Avanbees', the first Japanese medicinal toothpaste containing live lactic acid bacteria. |
| 2005-11 |
November 2005: Released the medicated toothpaste "Avanbees". |
| 2005-11 |
Released medicinal toothpaste 'Avanbees' |
| 2007-07 |
July 2007: Release of the glaucoma and ocular hypertension treatment drug "Nipradilol eye drops 0.25% 'Wakamoto'" (first product to adopt preservative‑free NP container). |
| 2007-07 |
Released glaucoma and ocular hypertension treatment 'Nipradilol 0.25% Wakamojo' (first product to use preservative-free NP container) |
| 2010-12 |
December 2010: Release of ophthalmic surgery adjunct "MakuAid intravitreal injection 40mg" (now ophthalmic surgery adjunct and ophthalmic corticosteroid "MakuAid eye injection 40mg"). |
| 2010-12 |
Released ophthalmic surgery adjunct 'MakuAid intravitreal injection 40mg' (now ophthalmic surgery adjunct and ophthalmic adrenal cortex hormone 'MakuAid eye injection 40mg') |
| 2014-04 |
April 2014: Moved headquarters to 2‑2‑2 Nihonbashi‑Honcho, Chuo‑ku, Tokyo. |
| 2014-04 |
Moved headquarters to 2-2-2 Nihonbashi Motomachi, Chuo-ku, Tokyo |
| 2015-10 |
October 2015: Release of supplement "OptiAid DE". |
| 2015-10 |
Released supplement 'OptiAid DE' |
| 2017 |
In 2017, we sold "AvanBees Oral Tablet", a processed food with a new lactic acid bacteria formulation suitable for oral care. |
| 2017 |
Sold 'Avanbees Oral Tablet', a processed food with new lactic acid bacteria suitable for oral care. |
| 2017-04 |
April 2017: Release of lactic acid bacteria‑containing processed food "AvanBees Oral Tablet". |
| 2017-04 |
Released lactic acid bacteria-containing processed food 'Avanbees Oral Tablet' |
| 2018 |
Developed products applying proprietary fermentation and cultivation technologies centered on 'Strong Wakamoto'. |
| 2018-10 |
October 2018: Release of allergy‑specific ophthalmic drug "Allergifence". |
| 2018-10 |
Released allergy-specific ophthalmic drug 'Allegifense' |
| 2019-08 |
August 2019: Release of functional food "OptiAid ML MACULAR". |
| 2019-08 |
Released functional food 'OptiAid ML MACULAR' |
| 2022-04 |
April 2022: Transitioned to the Tokyo Stock Exchange's new market category "Standard Market". |
| 2022-04 |
Transitioned to the Standard Market of the Tokyo Stock Exchange |
| 2023 |
Since 2023, we have begun selling femcare products (supplements, protein, etc.) that can be easily incorporated into daily life and provide counseling for women's concerns, thereby developing new businesses. |
| 2023 |
Launched femcare products (supplements, protein, etc.) that can be easily incorporated into daily life and provide women's counseling, creating a new business. |
| 2023-04 |
April 2023: Release of femtech brand "Femflora". |
| 2023-04 |
Release of femtech brand 'Femflora'. |
| 2025-06 |
June 2025: Release of multifocal intraocular lens "Aciravitrova Pro (Non‑toric)" featuring sinusoidal diffraction structure. |
| 2025-06 |
Launch of multifocal intraocular lens 'Aciravitro Nova Pro (Non-Topical)' with sinusoidal diffraction structure. |
| 2026 |
Conference presentation. |
| 2026-04-01 |
Assumed presidency. |
